Targeting EZH2 to improve treatment for prostate cancer
Official title: Development of Protein Degraders Targeting EZH2 Non-enzymatic Functions in Prostate Cancer
Funded at Emory University · NIH-10973062 · Data updated 2026-11-12
This study is looking at new ways to target a protein called EZH2 that helps prostate cancer grow, with the hope of creating better treatments for patients who aren't responding well to current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $663,713 |
| NIH project number | 1R01CA293596-01 |
| Project ID | NIH-10973062 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with prostate cancer, especially those who have developed resistance to standard treatments.
✕Less likely to help
Patients with early-stage prostate cancer who have not yet undergone treatment may not benefit from this research.
What this research studies
This research focuses on developing new protein degraders that specifically target the non-enzymatic functions of EZH2, a protein that plays a critical role in the progression of prostate cancer. By understanding how EZH2 contributes to cancer growth and resistance to treatment, the research aims to create innovative therapies that can effectively degrade EZH2 proteins. This approach could potentially overcome the limitations of current treatments that have not been successful in all cases of castration-resistant prostate cancer (CRPC). Patients may benefit from new treatment options that could improve survival rates and quality of life.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer, particularly for patients with castration-resistant forms of the disease.
How similar studies have gone: While targeting EZH2 has been explored in other studies, this specific approach using protein degraders is relatively novel and has not been extensively tested.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Yu, Jindan — Emory University
- Study coordinator: Yu, Jindan
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.